Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors.

IF 4 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2025-01-24 Epub Date: 2025-01-22 DOI:10.21037/tlcr-24-820

Takuya Watanabe, Masayuki Tanahashi, Eriko Suzuki, Naoko Yoshii, Takuya Kohama, Kensuke Iguchi, Takumi Endo

{"title":"Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors.","authors":"Takuya Watanabe, Masayuki Tanahashi, Eriko Suzuki, Naoko Yoshii, Takuya Kohama, Kensuke Iguchi, Takumi Endo","doi":"10.21037/tlcr-24-820","DOIUrl":null,"url":null,"abstract":"Background: Postoperative recurrence is a significant problem in patients with early-stage non-small cell lung cancer (NSCLC), with recurrence rates of 35% for stage IB and 50% for stage IIA. This study aimed to evaluate the efficacy of tegafur-uracil (UFT) as an adjuvant therapy in NSCLC patients with poor prognostic factors.Methods: A retrospective analysis was conducted of 330 patients with stage IB/IIA NSCLC who underwent lung resection between 2000 and 2019. Patients were divided into two groups based on the presence of poor prognostic factors (vascular, lymphatic, or pleural invasion or high pathological grade). Recurrence-free survival (RFS) and overall survival (OS) were compared between the UFT-treated and untreated groups using a Kaplan-Meier analysis.Results: Among these patients, 85.8% had poor prognostic factors. In patients with poor prognostic factors, the 5-year RFS rates in the UFT and non-UFT groups were 74.3% and 62.6%, respectively (P=0.048), and the 5-year OS was 85.6% and 62.4%, respectively (P<0.001). In patients without poor prognostic factors, UFT significantly extended OS (90.2% vs. 57.2%, P=0.03), but did not significantly affect RFS (P=0.40).Conclusions: Postoperative adjuvant therapy with UFT significantly improved both RFS and OS in patients with stage IB/IIA NSCLC with poor prognostic factors. The administration of UFT should be considered in patients with high-risk early-stage NSCLC.","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 1","pages":"139-149"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826286/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-820","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Postoperative recurrence is a significant problem in patients with early-stage non-small cell lung cancer (NSCLC), with recurrence rates of 35% for stage IB and 50% for stage IIA. This study aimed to evaluate the efficacy of tegafur-uracil (UFT) as an adjuvant therapy in NSCLC patients with poor prognostic factors.

Methods: A retrospective analysis was conducted of 330 patients with stage IB/IIA NSCLC who underwent lung resection between 2000 and 2019. Patients were divided into two groups based on the presence of poor prognostic factors (vascular, lymphatic, or pleural invasion or high pathological grade). Recurrence-free survival (RFS) and overall survival (OS) were compared between the UFT-treated and untreated groups using a Kaplan-Meier analysis.

Results: Among these patients, 85.8% had poor prognostic factors. In patients with poor prognostic factors, the 5-year RFS rates in the UFT and non-UFT groups were 74.3% and 62.6%, respectively (P=0.048), and the 5-year OS was 85.6% and 62.4%, respectively (P<0.001). In patients without poor prognostic factors, UFT significantly extended OS (90.2% vs. 57.2%, P=0.03), but did not significantly affect RFS (P=0.40).

Conclusions: Postoperative adjuvant therapy with UFT significantly improved both RFS and OS in patients with stage IB/IIA NSCLC with poor prognostic factors. The administration of UFT should be considered in patients with high-risk early-stage NSCLC.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.